α-シヌクレインへの小分子結合の分子基礎
Paul Robustelli1,2, Alain Ibanez-de-Opakua3, Cecily Campbell-Bezat1
1D. E. Shaw Research, New York, New York 10036, United States.
Journal of the American Chemical Society
|February 8, 2022
まとめ
分子ダイナミクスのシミュレーションにより,本質的に乱れたタンパク質アルファ・シヌクレインが薬物のファスジルとどのように結合するかが明らかになりました. このアプローチは 乱れたタンパク質に関連した疾患に対する 合理的な薬剤設計を可能にします
科学分野:
- 生物化学
- コンピュータ生物学
- 薬理学について
背景:
- 本質的に乱れたタンパク質 (IDP) は安定した3D構造を欠いており,薬の設計を複雑にする.
- アルファシヌクレインの蓄積はパーキンソン病に関連しています.
研究 の 目的:
- 分子ダイナミクス (MD) シミュレーションを使用して,アルファシヌクレインとファスジルの間の原子レベルの相互作用を理解する.
- 国内避難民を対象とした薬剤の設計のためのMDシミュレーションの可能性を調査する.
主な方法:
- 単体アルファシヌクレイン結合ファスジルの長期スケール,原子レベルのMDシミュレーション.
- シミュレーション結果を実験的なNMR化学シフトデータと比較する.
- 結合予測を検証するために,改造された小分子によるさらなるシミュレーションを行う.
主要な成果:
- MDシミュレーションは,アルファ-シナヌクレイン-ファスジル結合に関する既知のNMRデータを正確に再現した.
- ファスディル結合は,C端の近くでの充電-充電とπ-スタッキングの相互作用の間のダイナミックなシャットリングを伴う.
- 後のNMR実験は,MDシミュレーションによって予測された結合親和性と構造特性を確認した.
結論:
- MDシミュレーションは,IDP-リガンドの相互作用に関する原子レベルの洞察を提供します.
- 動的シャトルメカニズムは,ファスジル結合アルファシヌクレインの鍵です.
- MDベースの戦略は パーキンソン病のような病気の 本質的に乱れたタンパク質を標的とした 合理的な薬剤設計に有望です
さらに関連する動画
関連する概念動画
02:40Ligand Binding Sites
13.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.9K
00:49Ligand Binding and Linkage
5.0K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.0K
01:49Conserved Binding Sites
4.5K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.5K
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
235
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
235
03:03Amyloid Fibrils
10.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.5K
01:16Protein-Drug Binding: Mechanism and Kinetics
1.1K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.1K